Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mi Wang

Showing results (501-510 of 545) with videos related to

Pageof 55
Sort By:
Journal of Medicinal Chemistry|March 13, 2024
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor RegressionZhixiang Chen, Mi Wang, Dimin Wu, et al.
Neuroscience Bulletin|March 2, 2022
Pathological Networks Involving Dysmorphic Neurons in Type II Focal Cortical DysplasiaYijie Shao, Qianqian Ge, Jiachao Yang, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate CancerZhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Affective Disorders|March 2, 2023
The percentage of cognitive impairment in patients with major depressive disorder over the course of the depression: A longitudinal studyJin Liu, Yanjun Chen, Xinyu Xie, et al.
Plos One|September 21, 2017
Genetic and phenotypic effects of chromosome segments introgressed from Gossypium barbadense into Gossypium hirsutumWeiwu Song, Mi Wang, Wei Su, et al.
Journal of Medicinal Chemistry|September 23, 2024
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC DegraderAtsunori Kaneshige, Yiqing Yang, Longchuan Bai, et al.
Psychiatry Research|August 14, 2023
The longitudinal change pattern of cognitive subtypes in medication-free patients with major depressive disorder: a cluster analysisWeilong Guo, Bangshan Liu, Xiyu Wei, et al.
Nature Chemical Biology|February 2, 2023
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivoAtsunori Kaneshige, Longchuan Bai, Mi Wang, et al.
Journal of Affective Disorders|June 21, 2020
Connectome-based models can predict early symptom improvement in major depressive disorderYumeng Ju, Corey Horien, Wentao Chen, et al.
Journal of Medicinal Chemistry|November 7, 2024
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor RegressionRenqi Xu, Haibin Zhou, Longchuan Bai, et al.
Pageof 55

Showing results (501-510 of 545) with videos related to

Sort By:
Pageof 55
Journal of Medicinal Chemistry|March 13, 2024
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor RegressionZhixiang Chen, Mi Wang, Dimin Wu, et al.
Neuroscience Bulletin|March 2, 2022
Pathological Networks Involving Dysmorphic Neurons in Type II Focal Cortical DysplasiaYijie Shao, Qianqian Ge, Jiachao Yang, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate CancerZhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Affective Disorders|March 2, 2023
The percentage of cognitive impairment in patients with major depressive disorder over the course of the depression: A longitudinal studyJin Liu, Yanjun Chen, Xinyu Xie, et al.
Plos One|September 21, 2017
Genetic and phenotypic effects of chromosome segments introgressed from Gossypium barbadense into Gossypium hirsutumWeiwu Song, Mi Wang, Wei Su, et al.
Journal of Medicinal Chemistry|September 23, 2024
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC DegraderAtsunori Kaneshige, Yiqing Yang, Longchuan Bai, et al.
Psychiatry Research|August 14, 2023
The longitudinal change pattern of cognitive subtypes in medication-free patients with major depressive disorder: a cluster analysisWeilong Guo, Bangshan Liu, Xiyu Wei, et al.
Nature Chemical Biology|February 2, 2023
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivoAtsunori Kaneshige, Longchuan Bai, Mi Wang, et al.
Journal of Affective Disorders|June 21, 2020
Connectome-based models can predict early symptom improvement in major depressive disorderYumeng Ju, Corey Horien, Wentao Chen, et al.
Journal of Medicinal Chemistry|November 7, 2024
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor RegressionRenqi Xu, Haibin Zhou, Longchuan Bai, et al.
Pageof 55